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Objectives: Preterm birth contributes to a range of healthcare problems amongst 
infants surmounting to sizeable healthcare costs. Twin pregnancies are at particular 
risk of preterm birth. The objective of this study was to assess the cost-effectiveness 
of vaginal progesterone gel for the prevention of preterm birth in twin pregnancies.   
 
Methods: An economic evaluation was conducted alongside a randomized placebo 
controlled trial (the STOPPIT trial) of vaginal progesterone gel for the prevention of 
preterm birth in twin pregnancies. Five hundred women were recruited from nine 
maternity hospitals in the United Kingdom. The outcomes of the economic evaluation 
were presented in terms of net benefit statistics, cost-effectiveness acceptability  
curves, generated using the nonparametric bootstrap method, and the expected 
value of perfect information.  
 
Results: Mean health service costs between the period of randomization and 
discharge for mother and infant were £28,031 in the progesterone group and £25,972 
in the placebo group, generating a mean nonsignificant cost difference of £2,059 
(bootstrap mean cost difference £2,334; 95 percent confidence interval: −£5,023, 
£9,142; p = .33). The probability of progesterone being cost-effective was 20 percent 
at a willingness to pay threshold of £30,000 per preterm birth prevented. There is 
little economic justification for conducting further research into the use of vaginal 
progesterone gel in twin pregnancies for the prevention of preterm birth.   
 
Conclusions: Further studies of preventive interventions for preterm birth more 
generally are required given the scale of the clinical and economic burden of this 
condition. These studies should be sufficiently powered for economic endpoints and 
extend beyond hospital discharge.   
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In industrialized countries, the number of multiple pregnancies is increasing (4). 
Preterm birth (<37 weeks gestation) tends to be more prevalent in twin pregnancies 
(4). It is estimated that twins are over five times more likely to be born preterm than 
singletons and over 8 times more likely to be born <33 weeks gestation (17). That 
preterm birth contributes to long-term neurocognitive deficits, pulmonary dysfunction, 
and ophthalmologic disorders is well established in the literature (11;21;24). This, in 
turn, is associated with sizable healthcare costs from severe morbidity and 
neurological handicaps among preterm infants, not to mention the personal suffering 
of the families affected (18;19). For example, Petrou et al. (18) found that the 
duration of hospital admissions over the first 5 years of life for infants born at <28 and 
at 28 to 31 gestational weeks was eighty-five and sixteen times that for term infants, 
respectively. Cost differences persisted throughout the first 5 years of life of the child; 
the adjusted mean cost difference was estimated at over £14,000 for infants born at 
<28 weeks compared with term infants, and almost £12,000 for infants born at 28 to 
31 weeks compared with term infants (£ sterling, 1998 prices). The conditions 
associated with preterm birth also impose a substantial financial long-term burden on 
special education and other services. Given the clinical and economic burden of 
preterm birth, it is surprising that, to date, there are few effective measures to prevent 
the condition and interventions are mainly aimed at reducing neonatal morbidity and 
mortality once preterm birth has occurred. Although research exists on the use of 
progesterone for the prevention of preterm birth in selected high-risk singleton 
pregnancies (8), there remain unresolved issues in its use in twin pregnancies (22) 
and progesterone appears to be ineffective in higher order multiple pregnancies (5). 
To our knowledge, there are no published economic evaluations of progesterone for 
the use of preterm birth in twin pregnancies. In this study, we present the first results 
of their kind reporting an economic evaluation of vaginal progesterone gel for the 
prevention of spontaneous preterm birth in twin pregnancies based on the STudy of 
Progesterone for the Prevention of Preterm Birth In Twins (STOPPIT) trial (15).  
 
 
METHODS STOPPIT Trial The aim of the STOPPIT trial (15) was to determine 
whether vaginal progesterone gel reduces the rate of spontaneous preterm delivery 
in women with twin pregnancies. In brief, 500 women before 20 weeks gestation with 
a twin pregnancy were enrolled into a randomized controlled trial (RCT) from 
specialized antenatal clinics at nine UK National Health Service (NHS) hospitals 
between December 2004 and April 2008. Women were randomized either to daily 
progesterone gel (90 mg) (Crinone R _ ) or placebo gel; both were administered 
vaginally at home and starting at 24 weeks gestation. The primary clinical outcome 
was delivery or fetal death before 34 weeks gestation. Ethical approval was obtained 
from the West Glasgow Ethics Committee.  
 
Cost-effectiveness Analysis We performed a cost-effectiveness analysis that 
examined the incremental costs and incremental effectiveness of vaginal 
progesterone gel compared with placebo. Incremental costs (_C) were measured 
from the healthcare payer perspective (hospital costs only). Incremental 
effectiveness (_E) was estimated as the number of deliveries or fetal deaths before 
34 weeks gestation prevented (hereafter summarized as the number of preterm 
births prevented). The primary outcome of the economic evaluation was the net 
benefit (NB) statistic, NB = λ·_E-_C, where λ represents decision-makers’ willingness 
to pay threshold for a preterm birth prevented (23). The time horizon for costs and 
effects extended from randomization to hospital discharge of both mother and infant.  
 
Measurement of Resource Use Data were collected on all resources consumed in 
the hospital setting by each woman and infant during the period between 
randomization and hospital discharge. The use of other services provided by the 
community in the weeks between randomization and birth were not recorded in the 
STOPPIT trial and thus not amenable for our costing purposes. The data collection 
included duration of antenatal ward stays, labor ward stay, postnatal ward stay, 
neonatal care admissions, and maternal intensive care admissions. The trial data 
collection forms recorded the intensity of maternal and neonatal care, with the latter 
based on standard levels of care. The trial data collection forms also captured 
themethod of delivery (spontaneous vaginal delivery, vaginal breech, forceps or 
ventouse, or caesarean section) and ambulance transfers. The resources used for 
different modes of delivery were not captured through the trial data collection forms. 
We, therefore, conducted face-to-face interviews with clinicians and midwives, in 
conjunction with examination of clinical protocols to gauge the specific resources 
consumed and variations among centers with regard to staffing ratios, equipment 
used, drugs administered, and any estimates of disposable items used. This was 
imperative due to the high risk of caesarean section and instrumental delivery 
associated with twin pregnancies and enabled potential deviations from normal 
clinical care to be captured. Resource inputs were dependent upon the number of 
occupied bed-days in each inpatient ward, as occupancy rates affected the level of 
support that medical and nursing staff could provide to individual patients, which 
needed to be reflected in our cost estimates. The average cost per episode of care 
was therefore adjusted to reflect these rates, which were obtained from local hospital 
finance departments included in the trial.  
 
Valuation of Resource Use Unit costs for each resource item were obtained from a 
variety of sources. All unit costs followed guidelines on costing healthcare services 
as part of economic evaluation (9).An average per diem cost for nonintensive forms 
of maternity care was calculated by sending detailed questionnaires to each trial-
participating hospital, requesting cost data for the main resource categories of staff, 
drugs, disposables, equipment and overheads, and then apportioning these to 
different categories of care using a “top-down” methodology (13). Salary 
configurations were derived from national datasets as this source provided the most 
inclusive data (6). An average per diem cost for each level of neonatal care, as well 
as intensive care for the mother, and costs of ambulance transfers were derived from 
the national Department of Health schedule of reference costs (7). Reference costs 
are collected nationally for the vast majority of hospitals in England and Wales and 
are presented as average figures. They are calculated on a full absorption costing 
basis so that costs for each level of care include staff salaries, equipment, 
consumables and capital overheads. The cost of the progesterone gel was provided 
by Serono. Unit costs were combined with resource volumes to obtain a net cost per 
mother and infant during the trial period. This was then averaged across all trial 
participants, irrespective of the treatment center in which they were recruited, 
representing a common approach for multicenter economic evaluations (20). All 
costs were expressed in UK pounds sterling valued at 2008 prices.  
 
Data Analysis The data analysis was conducted on the basis of intention to treat. All 
results are reported as mean values with standard deviations and as mean 
differences in costs and effects with 95 percent confidence intervals (CIs) where 
applicable. We tested for differences in resource use and costs between the 
comparator groups using the independent-samples t-test procedure. Differences in 
costs and effects were considered significant if two-tailed p values were .05 or less. 
As the data for costs were skewed, we used nonparametric bootstrap estimation to 
derive 95 percent CIs for mean cost differences between the comparator groups (1). 
Using a large number of simulations, and based on sampling with replacement from 
the original data, the bootstrap method estimates the sampling distribution of a 
statistic (1). Each of these confidence intervals was calculated using 1,000 bias-
corrected bootstrap replications. The joint uncertainty surrounding the costs and 
effects was represented graphically on a cost-effectiveness plane (3). The probability 
that progesterone prophylaxis in twin pregnancies is cost-effective at alternative 
willingness to pay thresholds for the primary unit of health outcome was represented 
using the cost-effectiveness acceptability curve (CEAC) (10). We conducted 
sensitivity analyses (9) on key variables to ascertain the impact of certain 
assumptions on estimates of cost-effectiveness. Sensitivity analyses involved 
repeating the analysis while varying the assumptions. The variables chosen for the 
sensitivity analyses are explained in the results section. We also conducted a value 
of information analysis (10) to determine the value of collecting more information to 
inform decision makers as to the cost-effectiveness of vaginal progesterone gel to 
prevent preterm birth in twin pregnancies. The expected value of perfect information 
(EVPI) per woman was estimated by subtracting the total net benefit for the option 
we would choose based on current information from the maximum net benefit we 
would obtain with perfect information (the average of the maximum net benefit for 
each bootstrap replicated). All analyses were performed with a microcomputer 
running Excel version 2003 and STATA 9.0.  
 
RESULTS A total of 500 women were randomized in the trial: 250 to the active group 
and 250 to the placebo group (15). The groups were similar in terms of mean 
maternal age, mean gestational age at delivery, and number of previous pregnancies 
(15). Three mothers in each of the progesterone and the placebo groups were lost to 
follow-up (due to withdrawal of consent or not being traced); thus data from 494 
mothers were available (15). The proportions of women delivering before 34 weeks in 
the progesterone and placebo groups were 24.7 percent (61/247) and 19.4 percent 
(48/247), respectively, [odds ratio (OR) 1.36, 95 percent CI 0.89–2.09; p = .16], 
meaning that, for this population of women, vaginal progesterone gel did not reduce 
the incidence of preterm delivery (15). 
 
 
 Table 1 about here  
 
 
 
Health Service Resource Use Women allocated to the progesterone group spent, 
on average, a fewer number of days on the antenatal, labor, and postnatal wards 
than women allocated to the placebo group (Table 1), but these differences were not 
statistically significant. The number of neonatal days was greater, on average, for 
infants whose mothers received progesterone, but this was not statistically significant 
(p = .65). Although there were lower rates of both caesarean and instrumental 
delivery in the progesterone group, this also did not reach statistical significance.  
 
Health Service Costs There were no statistically significant differences between the 
two groups for any cost category or total costs (Table 2). Mean health service costs 
between the period of randomization and discharge for mother and infant were 
£28,031.33 in the progesterone group and £25,972.07 in the placebo group, 
generating a mean cost difference of £2,059.25 (bootstrap mean cost difference 
£2,334.01; 95 percent CI: −£5,023.01, £9,142.52) that was not statistically significant 
(p=.33). The cost of neonatal stays in special care, high dependency care, or 
intensive care, was the major cost component in the trial, largely because of the high 
staff and equipment costs associated with the care of preterm infants. Indeed, overall 
cost differences between the two groups can be largely explained by the additional 
care received by infants in the progesterone group during the neonatal period 
(bootstrap mean cost difference of £3,016.21; 95 percent CI: −£1,212.30, £7,244.30; 
p = .37), due to these infants’ greater length of stay. Conversely, more infants in the 
placebo arm were transferred to other units within the hospital or transferred by 
ambulance to other specialist centers. The cost of maternal intensive care was also 
higher among women who received progesterone rather than placebo, although the 
difference was not statistically significant. The cost of antenatal ward stays, labor 
ward stays, postnatal care, and complicated deliveries (caesarean sections or 
instrumental deliveries) were similar between the two arms of the trial, amounting to 
no statistically significant differences.  
 
 
 
Table 2 about here  
 
 
 
Sensitivity Analyses We performed sensitivity analyses to determine the impact 
that uncertainty surrounding individual parameter values might have. Varying hospital 
ward costs had no effect on the overall conclusions, because the progesterone arm 
remained more costly. For this, we used costs specific to two major hospitals in the 
trial and compared the cost-effectiveness findings with the original estimate which 
had used average standard unit costs across all centers. We found that the mean 
cost per woman was lower in both hospitals for the progesterone and placebo groups 
compared with our original analysis (between £23,460 and £24,561 in the placebo 
group and between £26,300 and £27,374 in the progesterone group) rendering 
vaginal progesterone gel to remain more costly than placebo. For our second 
sensitivity analyses, the duration of neonatal hospitalization in the placebo arm was 
set at the duration in the progesterone arm of the trial, as this represented the 
greatest cost difference between the two arms of the trial, despite limited clinical 
explanation for this difference. This did reduce the cost margin between the two arms 
of the trial but was insufficient to alter the overall finding, which is that vaginal 
progesterone gel is more costly overall.  
 
Cost-effectiveness Plane The uncertainty around the estimates of incremental 
costs and incremental effects is displayed in the cost-effectiveness plane (Figure 1). 
Although it is evident that the majority of bootstrapped samples of incremental cost 
and effect pairs are located in the northwest quadrant (where progesterone is less 
effective and more costly than placebo), samples fall in all four quadrants, resulting in 
a problem when interpreting a standard incremental cost-effectiveness ratio (ICER; 
_C/_E). That is, a negative ICER might represent improved outcomes and lower 
costs as a result of using progesterone, or worse outcomes and higher costs, but we 
are uncertain. This means that a meaningful ordering of the bootstrapped samples, 
which is required to make the confidence interval surrounding the ICER interpretable, 
is very difficult.  
 
CEAC and Net Benefit Statistic Under these circumstances, the CEAC and the net 
benefit statistic are the appropriate approaches to representing uncertainty 
surrounding the joint distribution of cost and effects (10). Re-examining Figure 1, the 
northeast quadrant,with positive costs and positive effects, and the south-west 
quadrant, with negative costs and negative effects, involve trade-offs. These two 
quadrants represent situations where vaginal progesterone gel may be cost-effective 
compared with placebo, depending upon whether the ICERis above or belowa 
threshold λ. The purpose of the CEAC is to summarize this uncertainty and is 
constructed by plotting the proportion of the cost and effect pairs that are cost-
effective for a range of monetary values, λ’s. Points in the northwest quadrant are not 
considered cost-effective whereas points in the southeast are always considered 
cost-effective. As the slope of the  ray is increased, points in the northeast and 
southwest quadrants may or may not be considered cost-effective depending upon 
the threshold. We can deduce from our data that there is a 20 percent chance that 
vaginal progesterone gel is costeffective in preventing preterm birth if society is 
willing to pay £30,000 per prevention. The net benefit statistic confirms these 
findings. Assuming that the willingness to pay threshold is £30,000 per preterm birth 
prevented, this generates a mean net benefit to the health services attributable to 
progesterone of −£3,637 (95 percent CI: −£3,853, −£3,420), meaning that there is a 
net loss to the health services in monetary terms. We found that at any given level of 
willingness to pay for preventing a preterm birth, there is a mean net loss as a result 
of using vaginal progesterone gel. This ranged from −£2,059 when λ = £0.00, to 
−£4,688 when λ = £50,000. 
 
Figure 1. Cost-effectiveness plane in terms of incremental costs (vertical axis) and 
incremental benefits (horizontal axis).  
 
Figure 2. Expected values of information analysis. 
 
  
 
Expected Value of Perfect Information There was no change in our findings after 
conducting the EVPI, which is that placebo currently has a higher expected value, 
and consistently using placebo would create a higher expected benefit. The expected 
value of perfect information was estimated at almost £100.00 per woman at a 
willingness to pay threshold of £30,000 per prevention of preterm birth (Figure 2). 
This translates into a nationwide EVPI of £1,033,400 based on an estimated number 
of twin pregnancies per annum in England and Wales (16).  
 
DISCUSSION Our study suggests that the probability of vaginal progesterone gel 
being cost-effective is low in women with twin pregnancies, where no study has 
preceded these health economic results, although future trials are intended to 
incorporate economic evaluation methodology (12). Our costeffectiveness estimates 
remained relatively robust following the sensitivity analyses that accounted for the 
uncertainty surrounding the values of parameters incorporated into the economic 
evaluation. Our EVPI analysis addressed the value of future research in this area and 
found that there is little value to conduct further economic research. Although we do 
not know decision-makers’ willingness to pay for the prevention of preterm birth, the 
EVPI should be a lot higher than the cost of future research in this area to justify it on 
economic grounds. Our study has the following strengths.We used advanced 
methods of economic evaluation, including methods for handling uncertainty and 
valuing future research in this area. In addition, the economic evaluation was based 
on a large RCT in which bias was eliminated through the random allocation of 
women to the study. A total of nine centers participated in the trial, making the study 
population fairly generalizable to other obstetric practices in the United Kingdom. 
There are three possible limitations of our study that should be borne in mind by 
readers. First, although our primary outcome measure has clinical relevance when 
evaluating the benefits of vaginal progesterone gel, decision makers such as the 
National Institute for Health and Clinical Excellence (NICE) in England and Wales, 
usually recommend preference based measures, such as quality-adjusted life-years 
(QALYs), for economic evaluation purposes (14). It was considered that the QALY 
metric would not be relevant for our study given the methodological problems 
associated with utility measurement in the perinatal context. However, stated 
preference discrete choice experiment and contingent valuation methods could, in 
principle, be used to  An economic evaluation of preventing preterm birth inform 
decision-makers’ willingness to pay values for the prevention of preterm birth. We 
would expect willingness to pay values to be high given the significant contribution of 
preterm birth to neonatal mortality and morbidity. Future research would benefit from 
concentrating on soliciting societal valuations for the benefits of preventing preterm 
birth. A second limitation of our study relates to the perspective and time horizon. 
Although we included hospital costs, we did not include costs outside of this setting, 
such as general practitioner and community visits, and we did not cost resources 
incurred after discharge from hospital. Although healthcare costs generally 
associated with preterm birth may be significant over the longer term, collecting this 
data would have been beyond the scope of the STOPPIT trial and we would not 
expect any significantly different results from our analysis here, given the 
nonsignificant clinical findings from the STOPPIT trial. Finally, our approach of using 
standard unit costs for key resource inputs may be considered to be a further 
limitation, given that these costs may be an inadequate reflection of costs specific to 
the treatment centers in which women and infants were recruited. An alternative, 
albeit less common approach, would have been to combine center specific unit cost 
data with all resource volume data for each patient, thereby calculating a treatment 
cost per patient, before averaging across patients (20). Using this approach could 
lead to a more accurate analysis because individual centers may respond to relative 
changes in unit cost of inputs to operate at a least cost input combination or technical 
efficiency. As a consequence, the calculations based on the use of standard unit 
costs, as opposed to center-specific unit costs, may have systematically 
overestimated costs. We addressed this issue, in part, in our study by conducting a 
parallel analysis, as part of our sensitivity analysis, which used resource unit costs 
specific to two hospitals in the trial, but there was no change in the conclusion of the 
study, which is that progesterone is more costly overall.  
 
POLICY IMPLICATIONS This study collected highly detailed resource use data 
amongstwomen randomized to receiving either progesterone or placebo for 
prophylactic treatment of preterm birth in twin pregnancies. Findings from the 
STOPPIT trial reveal that progesterone is neither clinically effective nor cost-effective 
with placebo consistently maintaining a higher net benefit than progesterone for the 
prevention of preterm birth in this sample of women. Other preventive treatments are 
urgently required to prevent preterm birth in twin pregnancies. Current evidence 
suggests that promising candidates in singleton pregnancies [progesterone (8) and 
cervical cerclage (2)] are ineffective in twin pregnancies. Trials of future therapies 
should be powered for relevant outcomes in women with multiple pregnancies: 
economic evaluation is likely to be required for clinically effective therapies before 
introduction into routine practice.  
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